Literature DB >> 3420355

[Spinal dural arteriovenous fistulae: exacerbation after myelography with metrizamide].

E Roullet1, J M Netter, J Chiras, F Mahieux, P Amarenco, R Marteau.   

Abstract

Metrizamide dorsal myelography was performed in two patients with minor to moderate sensorimotor paraparesis. Direct and indirect myelographic signs of spinal arteriovenous aneurysm were seen and spinal cord angiography showed thoracic dural arteriovenous fistulae (AVF) in both cases. Within 24 hours following myelography, clear neurological worsening occurred, associated with cephalalgia, nausea and transient diplopia in one case, leading to paraplegia in a few days. Paraplegia was complete six months after surgery in one case, and had resolved after embolization of fistula in the other patient. The mechanism of neurological worsening may include: substraction of cerebrospinal fluid, sitting position during and after myelography and local increase of metrizamide concentration secondary to impaired resorption caused by the fistula. Water-soluble myelography is of invaluable aid in the diagnosis of dural AVF and must be followed by early angiography, thus allowing prompt therapeutic embolization.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3420355

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  3 in total

1.  Sudden paraplegia after lumbar puncture as a clue in the diagnosis of a patient with spinal dural arteriovenous fistula.

Authors:  Carmen García-Cabo; Germán Morís
Journal:  Eur Spine J       Date:  2017-02-01       Impact factor: 3.134

2.  Post-myelography paraplegia in a woman with thoracic stenosis.

Authors:  Hesham M Soliman; Paul M Arnold; Ernest J Madarang
Journal:  J Spinal Cord Med       Date:  2013-05       Impact factor: 1.985

3.  A case of symptomatic spinal dural arteriovenous fistula after high-volume lumbar puncture.

Authors:  Thomas Noh; Rahul Chandra; Jimmy Kim; Ian Lee
Journal:  Surg Neurol Int       Date:  2017-08-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.